Introduction: Opioid-induced constipation (OIC) is the most common side effect of
INTRODUCTION
Chronic pain is a symptom that accompanies many conditions including joint pain, fibromyalgia, and osteoarthritis [1, 2] . In industrialized countries, opioids are frequently used alternatives for the treatment of moderate-to-severe chronic nonmalignant pain, second only to nonsteroidal anti-inflammatory agents in terms of prescription frequency [3] [4] [5] [6] . A total of 365 million opioid prescriptions were made globally in 2005 [1] . One in five people in Europe suffer from moderate-to-severe chronic non-cancer pain; 25-30% of those are prescribed opioids [3, 4, 7, 8] . One in four people in the United States (US) suffer from moderate-to-severe chronic non-cancer pain, and 15-20% of those groups are prescribed opioids [7, 9, 10] . Chronic non-cancer pain affects a quarter of the Canadian population, a third of which are prescribed strong opioids [11, 12] .
Opioid-induced constipation (OIC) is the most common side effect of opioid treatment in patients with cancer and non-cancer pain, and all patients using opioids are at risk of developing OIC [1] . OIC typically begins within the first few days of starting an opioid treatment, and although some patients may experience some relief with dose reduction of the opioid, it typically persists for over the treatment duration [1, 13] . The effects of OIC can cause psychological distress, bodily suffering, and social isolation [1, 14, 15] . The symptoms of OIC include rectal and/or lower abdominal pain, abdominal distension, straining during evacuation, bloating, and flatulence [16] [17] [18] . Stool impaction is a potential outcome of OIC that occurs when retained stools form large, firm lumps that are impossible to defecate, which in turn may lead to bowel obstruction, stercoral ulcers, and urinary retention [19] . This stage of OIC necessitates manual disimpaction or even surgery. Psychological distress is caused by OIC as a result of the general distress about the constipation itself as well as depressive symptoms and anticipatory anxiety, which may increase over time [16, 20] . The symptoms of OIC have a considerable negative impact on activities of daily living [1, 14] . It has been reported that constipation is even more common source of distress than the pain originally being treated [21] . In some patients, OIC becomes so severe that patients may taper or even discontinue opioid use in an attempt to relieve their discomfort, as they prefer tolerating their pain rather than suffering from continued bowel dysfunction [1, 14, 15, 18, [22] [23] [24] . Moreover, in contrast to other opioid-induced side effects (e.g., nausea), patients rarely develop a tolerance to OIC [1, 14, 17] . The low health state utility values in patients with OIC are most likely a result of both the chronic pain and the side effects of opioid treatment including OIC. For instance, patients with chronic lower back pain report EQ-5D scores ranging between 0.53 and 0.64 [32, 33] , and those with chronic cancer pain who required constipation therapy had a mean EQ-5D score of 0.49 [34] . To quantify the impact of OIC on a patients' health state utility, a comparison between patients with and without OIC, but who previously had OIC, is required. There is, however, limited published evidence of the impact of OIC on health state utility. A paper by Penning van Beest et al. estimated the EQ-5D in patients with a severe non-curable disease treated with opioids, and found that utility was much higher in those who were constipated than not constipated (0.65 vs. 0.31, respectively) [26] . However, this difference seems unreasonably large, and the study suffers from a number of limitations. It focused on constipation, in general, in opioid users, rather than OIC specifically, and the definition of constipation adopted by the study relied on self-reports of constipation and laxative use.
Most importantly, the study was cross-sectional and not designed to assess the causal impact of OIC on health state utility and did not control for other factors that may influence this. [37] .
The objective of the present analysis was to generate rigorous estimates of the impact of once daily 25 mg dose of naloxegol on the health state utility of LIR patients, the population for whom naloxegol has received market authorization in the EU; to examine if this utility impact of naloxegol is driven primarily by the change in OIC status, or whether the treatment has an impact beyond its impact on OIC status; and lastly to examine the utility impact of relief of OIC.
METHODS

Data Sources
The KODIAC trial program was designed to assess the efficacy and safety of naloxegol 12.5 and 25 mg in adult patients with OIC with the EQ-5D being collected in three studies in the program. The primary objective of both KODIAC 4 and 5 (ClinicalTrials.gov identifier, NCT01309841 and NCT01323790, respectively) was to evaluate the response of patients over a 12-week treatment period (see ''Introduction''), and the EQ-5D as an exploratory analysis. For these analyses, the data from the naloxegol 25 mg and placebo arms in the two trials were pooled, as the studies were of replicate design; both enrolled outpatients with non-cancer pain, aged 18-84, and were designed to ensure that C50% of the patients randomized were LIR at baseline. Across the two trials all arms had similar demographic and clinical characteristics enabling pooling, and this consistency was present in both the overall and LIR populations [38] . Moreover, the EQ-5D scores across trials were similar. In KODIAC 4, the placebo arm had 
Measures
The analysis was based upon the population of patients who were LIR, a subset of intent-to-treat population [37] , in correspondence with the EU label. These patients were those who had reported taking at least one laxative class for a minimum of four days within the two-week period prior to the screening visit concurrent with at least moderately severe symptoms of OIC (i.e., incomplete bowel movements, hard stools, straining, or false alarms).
In this analysis, OIC was defined as having fewer than 3 SBMs per week in any of the 2 weeks in the preceding 4-week rolling period. Non-OIC was defined as having 3 Health state utility was measured using the EQ-5D. First, the EQ-5D, a generic QoL instrument, was collected in all three trials. The EQ-5D is a self-administered, generic assessment tool developed by the EuroQol Group, a network of international research teams, and consists of questions on five dimensions of health (i.e., mobility, self-care, pain/discomfort, usual activities, and anxiety/ depression 
RESULTS
The baseline characteristics of LIR patients in KODIAC 4 and KODIAC 5 are reported in Table 1 .
Utility among LIR patients in the placebo arm was demonstrably lower than among patients in naloxegol arm at Week 12 and when pooling across Weeks 4 and 12 ( Table 2) .
Relative to placebo, the improvement in health state utility associated with treatment with naloxegol was 0.08 (p\0.05) at Week 12. Table 3 
The effect of treatment and OIC status on utility score, which was identified in Tables 2   and 4 , respectively, are likely to be related. Table 5 , below, presents the mean utility score of patients when segregated by treatment, time and OIC status. Table 5 Table 6 shows how responses to the five separate dimensions of the EQ-5D varied with treatment and OIC status in the LIR population. In Table 3 , which did not distinguish between OIC status following treatment, there was a statistically significant impact of treatment on anxiety/depression, and a borderline statistically significant impact on mobility. These treatment impacts are no longer observed in patients who are still constipated after treatment. However, the treatment impact is still observed in patients who are non-OIC after treatment, suggesting that naloxegol may reduce anxiety/depression and improve mobility, over and above any impact on these dimensions reflected in the measure of OIC status.
The analysis reported in Table 7 broadly supports the observations above that the key driver of health state utility is OIC status along with baseline utility, but a time and treatment effect does exist. When controlling for other relevant factors, it is estimated that relieving OIC is associated with a 0.05 health state utility improvement. The analysis also identifies a significant treatment-time interaction effect (p = 0.024), suggesting that naloxegol at Week 12 generates a utility improvement over and above its impact on OIC status.
Impact of treatment on health state utility was also captured in KODIAC 7. Table 8 suggests that the impact of treatment observed at 12 weeks is maintained to Week 16, though this impact is minimally observed at Week 24. It is important to note that these observations should be treated cautiously; they are based on the subset of participants who [41] . The current study adds to this literature by observing health state utility improvements in the EQ-5D. As well as being a validated EQ-5D EuroQol-five dimensions, OIC opioid-induced constipation, SD standard deviation * T test was used for the comparison instrument, and providing data compatible with the needs of those undertaking cost-utility analysis, the EQ-5D is a generic instrument which has the advantage of generating utility estimates comparable with those generated for many other indications.
Although we have demonstrated an impact on utility levels, an appropriate, indication specific, estimate of a minimum important difference (MID) is not in the published literature. Analyses in patients with OIC need to be undertaken to define this. Although Coretti et al. [42] concludes that there is a great amount of heterogeneity in estimates of MIDs due to variations in study populations and methodologies and in the absence of such an estimate, it is useful to observe that a 0.08 improvement represents a 14% improvement on the baseline utility of patients in trial, and is equivalent to the utility loss from the long-term consequences of a moderate stroke, profound hearing loss with ringing, or a dislocated shoulder [43] .
When a baseline utility score and OIC status were controlled for, the effect of treatment alone on health state utility disappears though treatment-time effect remains, suggesting that naloxegol has a lasting impact on utility over and above its impact on OIC status. This may point to the limitation of the binary measure of OIC improvement adopted in the study. The definition of OIC reflected recognized best practice, drawing on the Rome III diagnostic criteria for functional constipation [44] .
However, this measure would potentially miss some of the impact of treatment on health state utility if there is an improvement in OIC symptoms and the number of SBMs beyond that captured by the measure of OIC status. This caveat is supported by the trial data. In both KODIAC 4 and KODIAC 5, patients who were not constipated experienced more SBMs when on naloxegol than on placebo. Further work should be undertaken to explore the impact of changes in numbers of SBMs on utility score.
The analyses also suggest that change in OIC status is the most impactful driver of the improvement of OIC treatment on utility.
When other factors are controlled, relieving OIC is associated with a 0.05 improvement in health state utility. This estimate of the impact of OIC on utility is lower than those previously reported in the literature [26] , reflecting the limitations in the methods adopted in previous studies and the lack of face validity of their findings. Nevertheless, even at this lower level, The analysis of changes in the dimensions of the EQ-5D instrument suggest that the utility gain associated with naloxegol is primarily a result of improved mobility and reduced anxiety/depression, due to relief of OIC symptoms. No statistically significant change in the pain dimension of the EQ-5D instrument was observed, which was not unexpected given naloxegol being a treatment for OIC. However, a disadvantage of the EQ-5D is that its health state descriptive system is not always designed to be sensitive to certain medical conditions [45] . The EQ-5D describes only 5 dimensions, and has been shown to be less sensitive to conditions, such as vision problems [46] [47] [48] [49] [50] , diabetes, and arthritis. This could potentially lead to underestimation of the impact of indications on utility. For instance, the EQ-5D may miss the impact of OIC on social functioning. This concern has often led to the use of disease-specific instruments and mapping exercises to create utility scores based upon these disease specific instruments. One disease specific instrument developed for constipation is the Patient Assessment of Constipation Quality of Life questionnaire. This provides a brief but comprehensive assessment of the burden of constipation on patients' everyday functioning and well-being [51] . It is the most frequently used instrument to assess health related quality of life in patients with chronic constipation and is validated in this disease, but has not been specifically validated in patients with OIC [22] .
Finally, it should be reiterated that the EQ-5D was not the primary endpoint in the KODIAC trials. Consequently, the trials were 
CONCLUSION
Treatment of chronic pain with opioids is associated with many challenges, with OIC being an important factor due to its impact upon daily activities and health state utility. These analyses suggest that treatment with naloxegol improves patients' health state utility, and this is primarily driven by a change in the status of OIC.
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